# Temsirolimus as Second-line Therapy in HCC

> **NCT01567930** · PHASE2 · UNKNOWN · sponsor: **University of Tennessee Cancer Institute** · enrollment: 25 (estimated)

## Conditions studied

- Unresectable or Metastatic Hepatocellular Carcinoma

## Interventions

- **DRUG:** Temsirolimus

## Key facts

- **NCT ID:** NCT01567930
- **Lead sponsor:** University of Tennessee Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-02
- **Primary completion:** 2012-12
- **Final completion:** 2013-03
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2012-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01567930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01567930, "Temsirolimus as Second-line Therapy in HCC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01567930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*